Malcolm Brogdon (Indiana Pacers) with a 2-pointer vs the LA Clippers, 04/13/2021
Malcolm Brogdon (Indiana Pacers) with a 2-pointer vs the LA Clippers, 04/13/2021
Little Mix shared their Brit Awards Best British Group victory with all the girl bands who had been nominated before them.
The Eagles have a host of squad members out of contract this summer.
The stars were out in force at Tuesday night's event, serving up some seriously stylish looks.
Wendy's Co raised its annual forecast for earnings on Wednesday, betting that its breakfast menu, launched just before the lockdowns were announced last year, will bring in customers as restaurants reopen for dining after restrictions were eased. Wendy's now expects adjusted earnings to be between 72 cents and 74 cents per share and global systemwide sales to grow in the range of 8% to 10% for 2021. It had earlier forecast earnings between 67 cents and 69 cents per share and sales growth between 6% to 8% for the same period.
The three clubs were key drivers in the breakaway league’s official foundation on April 18 and did not join the other nine in backing down.
The European Union must recognise that Balkan countries seeking membership are losing faith in Brussels' long accession strategy, worsened by its initial failure to provide COVID-19 vaccines, according to an internal EU document seen by Reuters. Europe and the United States say that Albania, Bosnia, Kosovo, Montenegro, North Macedonia and Serbia will one day become members of the club of 27 states, following the ethnic wars of the 1990s that led to the disintegration of Yugoslavia. But China and Russia, whose trade and investment levels in the Balkans are far less than the EU's, are gaining influence, outsmarting the bloc by offering COVID-19 vaccines quickly during the pandemic.
The "Global Out-of-home Coffee Market - Growth, Trends, Covid-19 Impact, and Forecasts (2021-2026)" report has been added to ResearchAndMarkets.com's offering.
The former couple have been photographed together.
REHOVOT, Israel (AP) _ Kamada Ltd. (KMDA) on Wednesday reported first-quarter profit of $2.7 million. The Rehovot, Israel-based company said it had profit of 6 cents per share. The biopharmaceutical posted revenue of $24.9 million in the period. Kamada shares have dropped 9% since the beginning of the year. The stock has decreased 21% in the last 12 months. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a Zacks stock report on KMDA at https://www.zacks.com/ap/KMDA The Associated Press
No. 9/2021 Copenhagen, 12 May 2021 Closing of sale Referring to our Company announcement no 7 of 26 April 2021 we hereby inform that the Carve-out Sale of Lauritz.com A/S' subsidiaries in Sweden, Germany and Finland, including AB Stockholms Auktionsverk, has now be closed and thereby finalized. Change in reporting calendar With reference to the extension of the deadline for filing the annual report for 2020 (L225 approved by the danish parliament on 11 May 2021) we make the following changes to our reporting calendar: 31 May 2021: Annual report 2020The Annual General Meeting will be held in Copenhagen on 22 June 2021, 11 am. Best regards Lauritz.com Group A/S Bengt Sundström Chairman For press enquiries, please contact: Mette Jessen, E-mail email@example.com Certified Adviser: Erik Penser Bank AB Telephone number: +46 8-463 83 00 E-mail: firstname.lastname@example.org Market place: Nasdaq First North Growth Market Premier Stockholm This information is information that Lauritz.com Group A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, at 13.15 CEST on 12 May 2021.
VANCOUVER, British Columbia, May 12, 2021 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCB: BTHCF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company announces that NP-120 (Ifenprodil) reduced interleukin 6 (IL-6) with statistical significance in its recent Ifenprodil Phase 2b/3 COVID-19 trial, which may be informative for the Company’s ongoing Phase 2 trial of Ifenprodil for idiopathic pulmonary fibrosis (IPF) and chronic cough. The Company reports that in the COVID-19 trial, one of the biomarkers that was measured was the change in IL-6 levels. In the measurement from baseline to day five, IL-6 was reduced in the 20 mg treatment arm by 267 ng/L, versus 7 ng/L in the standard of care arm (values are adjusted mean concentrations; p = 0.0292). IL-6 acts as both a pro-inflammatory cytokine and an anti-inflammatory myokine and is encoded by the IL-6 gene. IL-6 can promote fibrosis by driving chronic inflammation and is elevated in patients with IPF.1 Blockade of IL-6 has been shown to attenuate pulmonary fibrosis in a mouse model.2 The effects of Ifenprodil on IL-6 may be helpful in better understanding its potential role as a possible therapeutic treatment for IPF. The company recently announced it had achieved 50% of its enrollment target for its Phase 2 trial of Ifenprodil for IPF and chronic cough. Changes in IL-6 will be measured in this study, along with other markers of fibrosis such as C-reactive protein and collagen pro-peptides. The Company advises that it is not making any express or implied claims that Ifenprodil has the ability to eliminate, cure or contain COVID-19 (or the SARS-2 Coronavirus) at this time. 1. https://www.nature.com/articles/s41420-021-00437-92. https://www.jimmunol.org/content/193/7/3755.long About Algernon Pharmaceuticals Inc. Algernon is a drug re-purposing company that investigates safe, already approved drugs, including naturally occurring compounds, for new disease applications, moving them efficiently and safely into new human trials, developing new formulations and seeking new regulatory approvals in global markets. Algernon specifically investigates compounds that have never been approved in the U.S. or Europe to avoid off label prescription writing. CONTACT INFORMATION Christopher J. MoreauCEOAlgernon Pharmaceuticals Inc.604.398.4175 ext email@example.com@algernonpharmaceuticals.comwww.algernonpharmaceuticals.com. The CSE does not accept responsibility for the adequacy or accuracy of this release. CAUTIONARY DISCLAIMER STATEMENT: No Securities Exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company leading the development of novel antibody drug conjugates (ADCs) to treat hematological malignancies and solid tumors, today announced that results of LOTIS-2, a multicenter, open-label, single-arm Phase 2 clinical trial evaluating the safety and efficacy of single-agent ZYNLONTA™ in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) following two or more systemic treatments, have been published online in The Lancet Oncology.
A handful of local areas have seen rates increase sharply in recent days.
German carmaker BMW plans to unveil a limited series hydrogen fuel cell model SUV in 2022 as the company continues to research zero-emission alternatives to battery-electric cars, the company's top executive said on Wednesday. Speaking at the carmaker's annual shareholder meeting, Chief Executive Officer Oliver Zipse said the company plans a small production run of a hydrogen fuel-cell powered x5 SUV next year. But BMW is one of a small number of carmakers that currently sees possibilities for the mass adoption of hydrogen fuel cells, which emit only water, and has said it is keeping its options open for the future.
“Besides to have a great director and a major star is like an added bonus,” says Disha Patani, whose film Radhe releases on 13 May.
TV celebrity stylist Lalla Bronshtein shares her top tips.
Tottenham fans want power on board amid concern of token gesture by clubTrust angry it was not consulted on advisory panel detailsApology for ESL involvement ridiculed as ‘three weeks’ late Tottenham fans protest against owners ENIC and chairman Daniel Levy after the club’s failed drive to join the European Super League last month. Photograph: Mark Leech/Offside/Getty Images
Dublin, May 12, 2021 (GLOBE NEWSWIRE) -- The "The US Postsecondary Online Education Market: Size, Trends and Forecasts (2021-2025 Edition)" report has been added to ResearchAndMarkets.com's offering. "The US Postsecondary Online Education Market: Size, Trends and Forecasts (2021-2025 Edition)", provides an in depth analysis of the postsecondary online education market of the US by value and by volume. The report provides a detailed analysis of the US postsecondary online education market by institution type. The postsecondary online education market can be segmented into undergraduate and graduate postsecondary education. Undergraduate postsecondary education is the formal education undertaken after completing the secondary school, while graduate postsecondary education generally known as post-graduation are the professional or research studies in various disciplines.Further, the US postsecondary online education market operates with the help of three types of institutions, namely, public not-for-profit, private not-for-profit and private for-profit institutions.The US postsecondary online education market has increased at a significant growth during the year 2020 and projections are made that the market would rise in the next four years at a significant CAGR i.e. 2021-2025 tremendously. The online postsecondary education market in the US is expected to increase due to increasing adoption of microlearning, rising urbanization rate, higher spending on education, growing penetration of IOT devices, increase in educational attainment, etc.Yet the market faces some challenges such as limited access to internet in remote areas, growing not-for-profit competitors, availability of free online content, etc. The postsecondary online education market also follows some market trends, which include growth of smart education and learning, artificial intelligence, learning management system, etc.The report also assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the US postsecondary online education market has also been forecasted for the period 2021-2025, taking into consideration the previous growth patterns, the growth drivers and the current and future trends.American Public Education, Grand Canyon Education, Adtalem Global Education and Apollo Global Management (Apollo Education Group) are some of the key players operating in the US postsecondary online education market, whose company profiling has been done in the report. In this segment of the report, business overview, financial overview and business strategies of the companies are provided.Company Coverage American Public EducationGrand Canyon EducationAdtalem Global EducationApollo Global Management (Apollo Education Group) Key Topics Covered: 1. Executive Summary2. Introduction2.1 Postsecondary Online Education: An Overview2.1.1 Introduction2.1.2 Online Program Management (OPM)2.1.3 Massive Open Online Courses (MOOCs)2.2 Postsecondary Online Education Segmentation2.2.1 Postsecondary Online Education Segmentation by Education Type2.2.2 Postsecondary Online Education Segmentation by School Type2.2.3 Postsecondary Online Education Segmentation by End User2.3 Postsecondary Online Education: Advantages and Disadvantages2.3.1 Postsecondary Online Education Advantages2.3.2 Postsecondary Online Education Disadvantages3. The US Market Analysis3.1 The US Postsecondary Online Education Market: An Analysis3.1.1 The US Postsecondary Online Education Market by Value3.1.2 The US Postsecondary Online Education Market by Volume3.1.3 The US Postsecondary Online Education Market Volume by Institution Type3.1.4 The US Postsecondary Online Education Market Value by Segments (Undergraduate and Graduate)3.1.5 The US Postsecondary Online Education Market Volume by Segments (Undergraduate and Graduate)3.2 The US Postsecondary Online Education Market: Segment Analysis3.2.1 The US Undergraduate Online Education Market by Value3.2.2 The US Undergraduate Online Education Market by Degree Programs3.2.3 The US Undergraduate Online Education Market by Volume3.2.4 The US Graduate Online Education Market by Value3.2.5 The US Graduate Online Education Market by Degree Programs3.2.6 The US Graduate Online Education Market by Volume4. Market Dynamics4.1 Growth Drivers4.1.1 Rise in Educational Attainment Rate4.1.2 Increase in Disposable Income4.1.3 Growing Penetration of IOT Devices4.1.4 Growth in Adoption of Microlearning4.1.5 Increasing Urbanization Rate4.1.6 Rising Education Spending4.2 Challenges4.2.1 Limited Access to Internet in Remote Areas4.2.2 Online Availability of Free Content4.2.3 Rising Not-for-Profit Competitors4.3 Market Trends4.3.1 Artificial Intelligence4.3.2 Smart Education and Learning4.3.3 Learning Management System 5. Competitive Landscape5.1 The US Postsecondary Online Education Market: A Financial Comparison 5.2 The US Postsecondary Online Education Market Volume by Players 6. Company Profiles6.1 American Public Education, Inc.6.1.1 Business Overview6.1.2 Financial Overview6.1.3 Business Strategy6.2 Grand Canyon Education, Inc.6.3 Adtalem Global Education Inc.6.4 Apollo Global Management (Apollo Education Group) For more information about this report visit https://www.researchandmarkets.com/r/4phoop CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager firstname.lastname@example.org For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Columbia Care Inc. (NEO: CCHW) (CSE: CCHW) (OTCQX: CCHWF) (FSE: 3LP) ("Columbia Care" or the "Company"), one of the largest and most experienced cultivators, manufacturers and providers of medical and adult-use cannabis products, today announced the launch of its new retail brand, Cannabist. More than a dispensary, Cannabist will serve as the intersection for medical and recreational cannabis users to provide a higher experience built on one of the largest customer data repositories, passion, technology innovation, community commitment and product standards.
With a cyberattack temporarily hobbling the critical Colonial Pipeline, the prospect of gas shortages in the Southeast is making some nervous.